141st APHA Annual Meeting

In This section

292227
Statin use and discontinuation among nursing home residents with advanced dementia

Tuesday, November 5, 2013 : 12:30 PM - 12:50 PM

Jennifer Tjia, MD, MSCE , Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA
Becky A. Briesacher, PhD , Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA
Daniel Peterson, MS , Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA
Susan Andrade, ScD , Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA
Sarah Cutrona, MD, MPH , Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA
Susan Mitchell, MD, MPH , Hebrew SeniorLife, Boston, MA
Background The use of statins in elderly individuals with advanced dementia near the end-of-life is controversial. Objective To describe statin use and impact of discontinuation in nursing home residents with advanced dementia. Methods We conducted a cohort study using 2007-2008 Medicare and Minimum Data Set data for 11,786 nursing home residents older than 65 years with recent progression to advanced stage dementia from 5 large states in the U.S.. Residents using statins were identified. Clinical characteristics and 28-day hospitalization risk were compared for residents who discontinued and continued statins. Multivariable Poisson regression controlled for age, sex, advance directives, functional status, eating problems, hospice enrollment, and geographic location of the nursing home. In addition, we conducted a sensitivity analysis using a self-controlled case series (SCCS) approach to examine the role of channeling bias in the risk estimation from the cohort approach. Results: Seventeen percent (17%) of residents with recent progression to advanced dementia (n=2,004) were prescribed statins. These residents had a mean age of 83.1 years, 70.3% were female, and used a mean of 10.2 other medications (SD 4.7, range 1-31). In follow-up, 32.4% (n=649) discontinued statin use. Twenty-five percent (25%) of discontinuations occurred within 30 days of decline, 13.6% between 30-90 days after decline, 9.8% between 90-180 days after decline, and the remaining 51.6% stopped >180 days after decline. Factors independently associated with discontinuation included residence in a nursing home in Florida relative to California; having a do-not-resuscitate order and hospice enrollment was associated with continuation. The 28-day hospitalization risk was higher for residents who discontinued statins compared to those who continued (adjusted incidence rate ratio [IRR] = 2.04, CI 1.61,2.58). The SCCS estimate for 28-day hospitalization risk following statin discontinuation compared to a 28-day pre-discontinuation control period was much lower than the cohort estimate (IRR = 0.79, CI 0.76, 0.83). Conclusion: A significant proportion of nursing home residents with dementia who use statins when they progress to advanced stage disease discontinue use. Hospitalization outcomes following discontinuation differ depending on method of estimation.

Learning Areas:
Chronic disease management and prevention
Epidemiology

Learning Objectives:
Describe prevalence of statin use and incidence of discontinuation among nursing home residents with advanced dementia Describe 28-day hospitalization risk following statin discontinuation compared to statin continuation. Using within person controls, to describe 28-day hospitalization in risk periods following statin discontinuation compared to pre-discontinuation risk periods

Keywords: Disease Management, Dementia

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have 10 years of experience as the principal or co-investigator of studies evaluating medication use. Among my scientific interests has been the quality of medication use in older adults residing in long-term care facilities.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.